Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile Infection in a Randomized Clinical Trial

Stuart H Cohen; Thomas J Louie; Matthew Sims; Elaine E L Wang; Asli Memisoglu; Barbara H McGovern; Lisa von Moltke

doi:10.1001/jama.2022.16476

Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile Infection in a Randomized Clinical Trial

JAMA. 2022 Nov 22;328(20):2062-2064. doi: 10.1001/jama.2022.16476.

Authors

Stuart H Cohen¹, Thomas J Louie², Matthew Sims³, Elaine E L Wang⁴, Asli Memisoglu⁴, Barbara H McGovern⁴, Lisa von Moltke⁴

Affiliations

¹ University of California Davis Health, Sacramento.
² Cumming School of Medicine University of Calgary, Calgary, Alberta, Canada.
³ Beaumont Health and Oakland University William Beaumont School of Medicine, Royal Oak, Michigan.
⁴ Seres Therapeutics, Cambridge, Massachusetts.

No abstract available

Plain language summary

This study examines adverse events and durability of response of SER-109, an investigational microbiome therapeutic comprised of purified Firmicutes spores, compared with placebo for Clostridioides difficile infection.

Publication types

Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Biological Therapy* / methods
Clostridioides difficile*
Clostridium Infections* / drug therapy
Clostridium Infections* / therapy
Follow-Up Studies
Humans
Microbiota*
Recurrence